PATENT CLAIM ANALYSIS

Application Number: 15744531
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2019-01
Patent Classification: ["514", "021200"]

Abstract:
The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.

Claim (Index 7):
The lipocalin mutein of  claim 1 , wherein the mutein comprises at least one of the following mutated amino acid residues in comparison with the linear polypeptide sequence of mature human tear lipocalin (SEQ ID NO: 1): Ser 14\u2192Pro; Asp 25\u2192Ser; Arg 26\u2192Ser, Phe, Gly, Ala, Asp or Glu; Glu 27\u2192Asp, Val or Thr; Phe 28\u2192Cys or Asp; Pro 29\u2192Phe, Leu or Trp; Glu 30\u2192Trp, Asn or Tyr; Met 31\u2192Ile, Val, Asp, Leu or Tyr; Asn 32\u2192Asp, Glu, Tyr, Trp, Val, Thr or Met; Leu 33\u2192Asp, Glu or Pro; Glu 34\u2192Val, Trp or His; Val 36\u2192Ala; Asn 48\u2192Asp; Lys 52\u2192Glu, Ser, Arg or Asn; Val 53\u2192Ala; Met 55\u2192Ala or Val; Leu 56\u2192Asp, Gln or Asn; Ile 57\u2192Leu; Ser 58\u2192Phe, Trp or Asp; Arg 60\u2192Phe or Glu; Cys 61\u2192Pro, Leu or Trp; Ala 66\u2192Asn; Ala 79\u2192Glu; Val 85\u2192Ala; Ala 86\u2192Asp; Cys 101\u2192Ser or Phe; Glu 104\u2192Tyr; Leu 105\u2192Cys or Gly; His 106\u2192Ala, Glu, Thr, Tyr, Gln or Val; Lys 108\u2192Tyr, Phe, Thr or Trp; Val 110\u2192Gly or Ala; Arg 111\u2192Pro; Gly 112\u2192Met or Thr; Lys 114\u2192Trp or Ala; Lys 121\u2192Thr; Ser 140\u2192Gly; and Cys 153\u2192Ser.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 86.0
- Lexical Diversity: 2.01316
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15371698', '14402438', '14208629', '14839222', '12865237']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8833876946672773
- 35 USC 102 Novelty (BERT): 0.6470302960154698
- Combined Prediction Score: 0.8597519548020965
- Mean Citation Score: 665.3214340000002
- Max Citation Score: 679.7365
- Similarity Product: 581.2032028281391

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test